Metformin association with lower prostate cancer recurrence in type 2 diabetes: A systematic review and meta-analysis

Asian Pacific Journal of Cancer Prevention

Volumn 16, Issue 2, 2015, Pages 595-600

  Hwang, In Cheol ^a   Park, Sang Min ^b   Shin, Doosup ^b   Ahn, Hong Yup ^c   Rieken, Malte ^d   Shariat, Shahrokh F ^e  

^a Gachon University   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Dongguk University   (South Korea)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Diabetes; Metformin; Prognosis; Prostate cancer

Indexed keywords

ANTIDIABETIC AGENT; METFORMIN;

DIABETES MELLITUS, TYPE 2; HUMAN; MALE; META ANALYSIS; PREVENTION AND CONTROL; PROGNOSIS; PROSTATIC NEOPLASMS; TUMOR RECURRENCE;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATIC NEOPLASMS;

EID: 84925396913     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2015.16.2.595     Document Type: Review

References (43)

1. Allott EH, Abern MR, Gerber L, et al (2013). Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database. Prostate Cancer Prostatic Dis, 16, 391-7.
2. Azvolinsky A (2014). Repurposing to fight cancer: the metformin-prostate cancer connection. J Natl Cancer Inst, 106, dju030.
3. Bansal D, Bhansali A, Kapil G, et al (2013). Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies. Prostate Cancer Prostatic Dis, 16, 151-8.
4. Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101.
5. Ben Sahra I, Laurent K, Giuliano S, et al (2010). Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res, 70, 2465-75.
6. Ben Sahra I, Laurent K, Loubat A, et al (2008). The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene, 27, 3576-86.
7. Benoit SR, Fleming R, Philis-Tsimikas A, Ji M (2005). Predictors of glycemic control among patients with Type 2 diabetes: a longitudinal study. BMC Public Health, 5, 36.
8. Bonanni B, Puntoni M, Cazzaniga M, et al (2012). Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol, 30, 2593-600.
9. Casa AJ, Dearth RK, Litzenburger BC, et al (2008). The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance. Front Biosci, 13, 3273-87.
10. Conteduca V, Di Lorenzo G, Bozza G, et al (2013). Metabolic syndrome as a peculiar target for management of prostate cancer patients. Clin Genitourin Cancer, 11, 211-20.
11. Currie CJ, Poole CD, Gale EA (2009). The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia, 52, 1766-77.
12. Currie CJ, Poole CD, Jenkins-Jones S, et al (2012). Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care, 35, 299-304.
13. Decensi A, Puntoni M, Goodwin P, et al (2010). Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila), 3, 1451-61.
14. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
15. Emami Riedmaier A, Fisel P, Nies AT, et al (2013). Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects. Trends Pharmacol Sci, 34, 126-35.
16. Evans JM, Donnelly LA, Emslie-Smith AM, et al (2005). Metformin and reduced risk of cancer in diabetic patients. BMJ, 330, 1304-5.
17. Freedland SJ, Aronson WJ (2009). Dietary intervention strategies to modulate prostate cancer risk and prognosis. Curr Opin Urol, 19, 263-7.
18. Garcia JA, Danielpour D (2008). Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther, 7, 1347-54.
19. Giovannucci E, Harlan DM, Archer MC, et al (2010). Diabetes and cancer: a consensus report. CA Cancer J Clin, 60, 207-21.
20. He XX, Tu SM, Lee MH, Yeung SC (2011). Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Ann Oncol, 22, 2640-5.
21. Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58.
22. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K (2009). Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res, 69, 7507-11.
23. Jiralerspong S, Palla SL, Giordano SH, et al (2009). Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol, 27, 3297-302.
24. Kaushik D, Karnes RJ, Eisenberg MS, et al (2014). Effect of metformin on prostate cancer outcomes after radical prostatectomy. Urol Oncol, 32, 1-7.
25. Landman GW, Kleefstra N, van Hateren KJ, et al (2010). Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care, 33, 322-6.
26. Li C, Zhao G, Okoro CA, et al (2013). Prevalence of diagnosed cancer according to duration of diagnosed diabetes and current insulin use among U.S. adults with diagnosed diabetes: findings from the 2009 behavioral risk factor surveillance system. Diabetes Care, 36, 1569-76.
27. Libby G, Donnelly LA, Donnan PT, et al (2009). New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care, 32, 1620-5.
28. Margel D, Urbach DR, Lipscombe LL, et al (2013). Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol, 31, 3069-75.
29. Niraula S, Dowling RJ, Ennis M, et al (2012). Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat, 135, 821-30.
30. Niraula S, Pond G, de Wit R, et al (2013). Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study. Can Urol Assoc J, 7, 74-81.
31. Patel T, Hruby G, Badani K, et al (2010). Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin. Urology, 76, 1240-4.
32. Peehl DM, Stamey TA (1986). Serum-free growth of adult human prostatic epithelial cells. In Vitro Cell Dev Biol, 22, 82-90.
33. Pollak M (2008). Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer, 8, 915-28.
34. Pollak MN (2012). Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov, 2, 778-90.
35. Rieken M, Kluth LA, Xylinas E, et al (2014). Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer. World J Urol, 32, 999-1005.
36. Sarma AV, Jaffe CA, Schottenfeld D, et al (2002). Insulin-like growth factor-1, insulin-like growth factor binding protein-3, and body mass index: clinical correlates of prostate volume among Black men. Urology, 59, 362-7.
37. Sciacca L, Vigneri R, Tumminia A, et al (2013). Clinical and molecular mechanisms favoring cancer initiation and progression in diabetic patients. Nutr Metab Cardiovasc Dis, 23, 808-15.
38. Sikka S, Chen L, Sethi G, Kumar AP (2012). Targeting PPARgamma signaling cascade for the prevention and treatment of prostate cancer. PPAR Res, 2012, 968040.
39. Snyder CF, Stein KB, Barone BB, et al (2010). Does pre-existing diabetes affect prostate cancer prognosis? a systematic review. Prostate Cancer Prostatic Dis, 13, 58-64.
40. Song CW, Lee H, Dings RP, et al (2012). Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Sci Rep, 2, 362.
41. Spratt DE, Zhang C, Zumsteg ZS, et al (2013). Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol, 63, 709-16.
42. Stroup DF, Berlin JA, Morton SC, et al (2000). Meta-analysis of observational studies in epidemiology: a proposal for reporting. meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA, 283, 2008-12.
43. Suissa S, Azoulay L (2012). Metformin and the risk of cancer:.